A study from the Employee Benefit Research Institute (EBRI), supported by the Blue Cross Blue Shield Association and other partners, estimates that GLP-1 coverage would be a major premium driver for employer-provided coverage
And that was the first time I was able to say as an obesity medicine specialist that if I give you this drug, I can likely improve your life and reduce your chance of dying from cardiovascular disease
You still enjoy eating, but it doesnt drive behavior in the same way. That mechanism has sparked interest far beyond obesity research
These divergent effects appear to be modulated by multiple factors, including treatment duration, drug concentration, cancer type, and patient-specific parameters such as genetic background and comorbidities [9, 19]
The combination of metformin with semaglutide or metformin with tirzepatide may offer the most comprehensive approach for former gestational diabetes patients